20 patents
Utility
Compounds useful as kinase inhibitors
28 Nov 23
This invention relates to novel compounds.
Nicolas Guisot
Filed: 12 Nov 21
Utility
Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
7 Nov 23
Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
Filed: 13 Aug 21
Utility
Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
1 Nov 22
A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.
Mark Reynolds, Steven A Smith
Filed: 27 Apr 20
Utility
Compounds useful as kinase inhibitors
18 Oct 22
This invention relates to novel compounds.
Nicolas Guisot
Filed: 15 Dec 20
Utility
Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
4 Jan 22
Mark Reynolds, Charles Todd Eary, Stacey Spencer, Derrick Juengst, Bruno Hache, Yutong Jiang, Julia Haas, Steven W. Andrews
Filed: 18 May 17
Utility
Methods of treating pediatric cancers
7 Dec 21
A method of treating a pediatric cancer in a subject in need thereof.
Michael Cox, Nisha Nanda
Filed: 10 Jan 20
Utility
Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrile
24 Aug 21
Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
Filed: 16 Jun 20
Utility
Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
17 Aug 21
Qian Zhao, Stacey Spencer, Yutong Jiang, Julia Haas, Charles Todd Eary
Filed: 26 Oct 17
Utility
Compounds useful as kinase inhibitors
16 Feb 21
This invention relates to novel compounds.
Nicolas Guisot
Filed: 13 May 20
Utility
Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
2 Feb 21
Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
Nisha Nanda, Joshua H. Bilenker, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
Filed: 3 Jan 18
Utility
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile
28 Sep 20
6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.
Mark Reynolds, Charles Todd Eary
Filed: 9 Oct 18
Utility
Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
17 Aug 20
Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
Filed: 9 Oct 18
Utility
Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
27 Jul 20
Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
Nisha Nanda, Joshua H. Bilenker, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
Filed: 25 Oct 16
Utility
Compounds useful as kinase inhibitors
29 Jun 20
This invention relates to novel compounds.
Nicolas Guisot
Filed: 15 Dec 16
Utility
Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
1 Jun 20
A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.
Mark Reynolds, Steven A. Smith
Filed: 25 Nov 18
Utility
Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
18 May 20
Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
Nisha Nanda, Joshua H. Bilenker, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
Filed: 15 Oct 17
Utility
Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
6 Apr 20
This invention relates to novel compounds.
Nicolas Guisot
Filed: 15 Sep 16
Utility
Methods of treating pediatric cancers
16 Mar 20
A method of treating a pediatric cancer in a subject in need thereof.
Michael Cox, Nisha Nanda
Filed: 2 Jan 18
Utility
Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase
20 Jan 20
Mathew Calder, Nicolas Guisot
Filed: 10 May 18
Utility
Compounds useful as kinase inhibitors
4 Nov 19
This invention relates to novel compounds.
Nicolas Guisot
Filed: 26 Aug 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first